Alzheimer Hastalığında Güncel Tedaviler: Yeni Yaklaşımlar ve Gelecek Perspektifleri
Özet
“Alzheimer Hastalığında Güncel Tedaviler: Yeni Yaklaşımlar ve Gelecek Perspektifleri” başlıklı bu bölüm, Alzheimer hastalığı (AH) tedavisindeki en son gelişmeleri ele almaktadır. Demansın en yaygın formu olan AH, ilerleyici bilişsel kayıpla karakterizedir. Bölüm, amiloid-beta birikimi, tau proteini agregasyonu, nöroinflamasyon, glenfatik sistem disfonksiyonu ve sinaptik kayıp gibi hastalığın patofizyolojisini incelemektedir. FDA onaylı kolinesteraz inhibitörleri ve NMDA reseptör antagonistleri gibi mevcut tedavilerin yanı sıra, anti-amiloid monoklonal antikorlar (aducanumab, lecanemab, donanemab), tau hedefli tedaviler ve nöroinflamasyonu modüle eden ilaçlar gibi hastalık modifiye edici yeni tedaviler değerlendirilmiştir. Deneysel tedavilere ve AH tedavisinde karşılaşılan zorluklara da değinilen bölüm, erken müdahale ve kişiselleştirilmiş tedavilerin önemine vurgu yapmaktadır. AH’nin multifaktöriyel doğası nedeniyle, çoklu hedefli yaklaşımların benimsenmesi gerektiği vurgulanmaktadır.
The chapter “Current Treatments for Alzheimer’s Disease: New Approaches and Future Perspectives” explores the latest advancements in Alzheimer’s disease (AD) treatment. AD, the most common form of dementia, is characterized by progressive cognitive decline. The chapter discusses the pathophysiology of AD, including amyloid-beta accumulation, tau protein aggregation, neuroinflammation, glymphatic system dysfunction, and synaptic loss. It reviews current FDA-approved treatments such as cholinesterase inhibitors and NMDA receptor antagonists, alongside novel disease-modifying therapies, including anti-amyloid monoclonal antibodies (aducanumab, lecanemab, donanemab), tau-targeted therapies, and neuroinflammation-modulating drugs. The discussion extends to experimental therapies and the challenges in AD treatment, emphasizing the need for early intervention and personalized medicine. The chapter underscores the importance of multi-target approaches to address the complex nature of AD and highlights emerging strategies to improve patient outcomes.
Referanslar
International AD, Wimo A, Ali GC, et al. World Alzheimer Report 2015: The global impact of dementia: An analysis of prevalence, incidence, cost and trends. Published online September 21, 2015. Accessed February 21, 2025. https://www.alzint.org/resource/world-alzheimer-report-2015/
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet Lond Engl. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015;52:1-18. doi:10.1016/j.npep.2015.06.008
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189. doi:10.1101/cshperspect.a006189
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement N Y N. 2018;4:575-590. doi:10.1016/j.trci.2018.06.014
Cai Y, Zhang Y, Leng S, et al. The relationship between inflammation, impaired glymphatic system, and neurodegenerative disorders: A vicious cycle. Neurobiol Dis. 2024;192:106426. doi:10.1016/j.nbd.2024.106426
Ittner A, Ittner LM. Dendritic Tau in Alzheimer’s Disease. Neuron. 2018;99(1):13-27. doi:10.1016/j.neuron.2018.06.003
Arendt T, Brückner MK, Morawski M, Jäger C, Gertz HJ. Early neurone loss in Alzheimer’s disease: cortical or subcortical? Acta Neuropathol Commun. 2015;3:10. doi:10.1186/s40478-015-0187-1
Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain J Neurol. 2018;141(7):1917-1933. doi:10.1093/brain/awy132
Husna Ibrahim N, Yahaya MF, Mohamed W, Teoh SL, Hui CK, Kumar J. Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty. Front Pharmacol. 2020;11:261. doi:10.3389/fphar.2020.00261
Zhang Y, Sun Y, Hu X, Yao Y, Wang J. The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with Alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs. Int J Surg Lond Engl. 2024;110(6):3937-3945. doi:10.1097/JS9.0000000000001381
Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61-67. doi:10.1016/j.coph.2005.09.007
Perneczky R, Dom G, Chan A, Falkai P, Bassetti C. Anti-amyloid antibody treatments for Alzheimer’s disease. Eur J Neurol. 2024;31(2):e16049. doi:10.1111/ene.16049
Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain J Neurol. 2023;146(11):4414-4424. doi:10.1093/brain/awad188
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis. 2022;9(2):197-210. doi:10.14283/jpad.2022.30
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
Mummery CJ, Börjesson-Hanson A, Blackburn DJ, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29(6):1437-1447. doi:10.1038/s41591-023-02326-3
Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO. Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. J Prev Alzheimers Dis. 2022;9(4):780-790. doi:10.14283/jpad.2022.63
Wang ZJ, Li XR, Chai SF, et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer’s disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023;240:109716. doi:10.1016/j.neuropharm.2023.109716
Dubois B, López-Arrieta J, Lipschitz S, et al. Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther. 2023;15(1):39. doi:10.1186/s13195-023-01169-x
Reading CL, Ahlem CN, Murphy MF. NM101 Phase III study of NE3107 in Alzheimer’s disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021;11(4):289-298. doi:10.2217/nmt-2021-0022
Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res Ther. 2021;13(1):62. doi:10.1186/s13195-021-00795-7
Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial. JAMA Neurol. 2023;80(12):1307-1316. doi:10.1001/jamaneurol.2023.3810
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2024. Alzheimers Dement Transl Res Clin Interv. 2024;10(2):e12465. doi:10.1002/trc2.12465
Jia J, Ning Y, Chen M, et al. Biomarker Changes during 20 Years Preceding Alzheimer’s Disease. N Engl J Med. 2024;390(8):712-722. doi:10.1056/NEJMoa2310168
Nicoll JAR, Barton E, Boche D, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65(11):1040-1048. doi:10.1097/01.jnen.0000240466.10758.ce
Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33. doi:10.1126/scitranslmed.3002609
